| Literature DB >> 18958288 |
Alison Wringe1, Paul E M Fine, Roland W Sutter, Olen M Kew.
Abstract
BACKGROUND: Eight outbreaks of paralytic polio attributable to circulating vaccine-derived poliovirus (cVDPV) have highlighted the risks associated with oral poliovirus vaccine (OPV) use in areas of low vaccination coverage and poor hygiene. As the Polio Eradication Initiative enters its final stages, it is important to consider the extent to which these viruses spread under different conditions, so that appropriate strategies can be devised to prevent or respond to future cVDPV outbreaks. METHODS ANDEntities:
Mesh:
Substances:
Year: 2008 PMID: 18958288 PMCID: PMC2570794 DOI: 10.1371/journal.pone.0003433
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Summary of reported cVDPV outbreaks with corresponding estimated number of infections
| Country | Number of reported cases | Type | Date of onset of index case | Est. duration of virus circulation | Estimated number of cVDPV infections | References |
| Hispaniola (pop | 21 VC & 21 PC | 1 | July 2000 | ∼2 years | 100,000–200,000 |
|
| Madura, Indonesia (pop: 3.5 million) | 46 VC and 10 PC | 1 | June 2005 | ∼2 years | 100,000+ |
|
| Egypt (pop: 55.8 million) | 30 VC | 2 | 1988 | ∼10 years | Several million |
|
| Philippines (pop: 75.7 million) | 3 VC | 1 | March 2001 | ∼3 years | 1,000–10,000 |
|
| Madagascar (pop: 16 million) | 4 VC | 2 | March 2002 | ∼2.5 years | 10,000–50,000 |
|
| China (pop: 1.3 billion) | 3 VC | 1 | May 2004 | ∼1 year | 1,000–10,000 |
|
| Madagascar (pop: 16 million) | 5VC | 2 | April 2005 | ∼1.5 years | 10,000–50,000 |
|
| Cambodia (pop: 14 million) | 2 VC | 3 | Nov 2005 | ∼2 years | 1,000–10,000 |
|
VC (virologically-confirmed), PC (polio-compatible)
approximate population size at the time of the outbreak
Figure 1Geographic distribution of virologically-confirmed cases (represented by grey circles) and polio compatible cases (represented by filled stars) associated with type 1 cVDPV outbreak in Hispaniola between July 2000 and July 2001.
Environmental samples that were positive for type 1 cVDPV isolates are represented by light grey triangles.
Figure 2(adapted from ; Kew et al. 2002 Science 296: 356:359)Temporal distribution of virologically-confirmed and compatible cVDPV cases (grey bars) in Haiti (left hand panel) and in the DR (right hand panel), plotted against the left axis.
The estimated number of infections (dotted lines) between the estimated date of the initiating infection and the end of the outbreak is shown against the right hand axis. The number and temporal distribution of these infections represents our best estimate, assuming infection peaks during the summer months, average case ascertainment of 20% in Haiti, and 50% in the DR, and constant case to infection ratios of 1∶200 (----) or 1∶1000 (- - -). Black arrows indicate the dates of NIDs, dashed arrows represent sub-optimal NIDs (in Haiti), and the smaller arrows represent the rolling immunisation campaign in Haiti between May and July 2001.
Figure 3(adapted from ; Estivariz et al. 2008 JID 197: 347–354) Geographic distribution of virologically-confirmed and polio-compatible type 1 cVDPV cases on Madura, Indonesia between June and October 2005.
Population density in Madura for 2005 is shown by district
Figure 4Temporal distribution of virologically-confirmed (grey bars) and compatible cVDPV cases (dashed bars) in Madura, plotted against the left axis. The estimated number of infections (dotted lines) between the estimated date of the initiating infection and the end of the outbreak is shown against the right hand axis.
The number and temporal distribution of these infections represents our best estimate, assuming average case ascertainment of 80%, and constant case to infection ratios of 1∶200 (----) or 1∶1000 (- - -). Black arrows indicate the dates of NIDs.
Figure 5Geographic distribution of virologically-confirmed type 2 cVDPV cases in Egypt between 1988 and 1993.
Individual cases are represented by filled circles of different sizes to show the year of paralysis onset. Population density for Egypt in 1990 is shown by governorate.
Figure 6(From: Yang et al, J Virol 2003; 77:8366–8377) Estimate of the date of initiating OPV dose from the rate of accumulation of synonymous substitutions into VP1 among the 28 type 2 cVDPV isolates for which the dates of sample collection are known.
Abscissa: date of sample collection for each isolate. Ordinate: Ks, the number of substitutions (Sabin 2 sequence set to zero substitutions) at synonymous sites in VP1. The evolution rate was estimated by weighted linear regression. The 95% CI for the estimated date of the initiating OPV dose, July 1979 to March 1986, is bounded by parentheses along the abscissa.
Figure 7The distribution of reported cVDPV cases in Egypt (grey bars) is shown on the left hand axis. The estimated number of infections (dotted line) between 1983 (when the initiating infection is estimated to have occurred) and the end of the outbreak is plotted against the right hand axis, and represents a best estimate of the distribution of infections.
The approximation for the number of infections is represented by the area under the curve, and assumes a constant case to infection ratio of 1∶1000, and average case ascertainment of ∼10%.
Summary of estimated number of cVDPV infections associated with five small-scale cVDPV outbreaks
| PHILIPPINES (type 1) | MADAGASCAR (type 2) | CHINA (type 1) | MADAGASCAR (type 2/3) | CAMBODIA (type 3) | |
| Space-time pattern | 3 cases & 1 infected contact between 03–09/2001 on 2 islands 800 km apart; ferry link | 4 cases between 03–04/2002 in 3 rural villages in the south-east of the country. | 3 cases & 4 infected contacts between 05–08/2004 in 2 villages 40 km apart | 5 cases & 12 infected contacts between 04–08/2005 in 5 districts of a rural province in SW of the country | 2 VC cases in the capital in 11/05 & 01/06 |
| Population immunity | WPV eradicated in 1993; Sub-optimal NIDS since 2000 Up to 2 million susceptible <5 yrs | WPV eradication in 1997; Last NIDs in 1999 with coverage >90%; Routine OPV3 coverage <40% in 2001; ∼1 million susceptible < 5 yrs in 2001 | WPV eradication in 1994. Vaccination coverage <70% in affected villages since 1995. Up to 3.5 million susceptible <5 yrs in affected province (∼1,000 in affected villages) | WPV eradication in 1997; Prior type 2 cVDPV in 2002; Despite SIAs in 2002, routine OPV3 coverage in affected areas <50%; ∼0.8 million susceptible <5 y (mostly <3y) | WPV eradication in 1997; Routine OPV3 overage 82%; but <50% around cases; ∼1 million susceptible <5 yrs |
| Age distribution of cases | 3 cases and infected contact were 8, 3, 1 and 3 yrs old | 4 cases aged 6, 9, 14 and 20 mths old | Cases aged 0.9–3.2 yrs; contacts aged 1.4–7.3 yrs | Cases aged 2–3 yrs old; contacts 0.7–6 yrs old | Cases aged ∼18 mths |
| Ascertainment and response | Index case confirmed cVDPV within 3 mths of virus isolation; 3 OPV rounds, beginning Dec 2001; reported coverage >95%; no further isolations | OPV rounds in affected areas after 8 mths & NIDs after 11 mths; ∼0.5 million children (15% of target) missed NIDs; | Province-wide OPV campaign for <5 yr olds in 08/04; no further isolations of the outbreak strain | 2 rounds of SIAs in Sept and Oct 2005; no further cases reported | 3 OPV rounds in March-May 06 in high-risk areas; no further virus isolations |
| Surveillance | Annual non-polio AFP rates in decline since 2001; substantial variation within districts in collection rates for adequate stool specimens. | Poor AFP surveillance indicators in year prior to outbreak (∼1/4 non-polio AFP cases reported | Very poor AFP surveillance in affected province in 2004 (<0.1 non-polio AFP/100,000 pop <15); | Poor AFP surveillance indicators in the affected province during the period leading up to the outbreak | Non-polio AFP rates in Phnom Penh and nationwide ∼2/100,000 population <15 yrs prior to the reported cVDPV cases |
| Social characteristics of cases | Index case from slum area; 2nd & 3rd cases related | Cases related & had history of recent contact | Low population density, very poor & remote villages | 4/5 cases in poor, rural villages; 1 case with recent travel history | Cases occurred in very poor communities in the capital |
| deDivergence of VDPV isolates from the reference OPV strain | 3% VP1 sequence difference from Sabin 1: circulating for ∼3 yrs. | ∼2.5% VP1 sequence difference from Sabin2: circulation for ∼2.5 yrs. | 1–1.2% VP1 sequence difference from Sabin1: circulation for ∼1 yr. | 1.1–1.8 % VP1 sequence difference from Sabin2: circulation for ∼1.5 yrs. | 1.9–2.4 % VP1 sequence difference from Sabin 2; circulation for ∼2 yrs. |
| Degree of genetic diversity among cVDPV isolates | Isolates formed single cluster, with high degree of sequence similarity; consistent with narrow chain of transmission. | Isolates formed 2 sub-groups, but > 99% sequence homology in VP1; consistent with narrow chain of transmission. | naIsolates diverged from common ancestor ∼5–6 months before detection of outbreak | 3×type 2 lineages with multiple transmission chains & 1 type 3 lineage along a unique and independent chain | The two isolates shared only ∼50% of substitutions, consistent with ∼8 months of independent circulation |
| Type-specific properties | Type 1 least virulent of Sabin strains, consistent with large number of infections prior to identification of index case. | Sabin 2 most transmissible; reversion towards wild phenotype may be more rapid than for Sabin 1or 3 | Type 1 least virulent of Sabin strains, consistent with large number of infections prior to identification of index case. | 2nd type 2 cVDPV outbreak in Madagascar may suggest ideal conditions for emergence and spread of cVDPV | Type 3 most virulent of Sabin strains; consistent with fewer infections prior to identification of index case |
| Case-to-infection ratio | 2 case isolates had same virulence as WPV1 when tested in transgenic mouse model; likely to be 600–3000 infections associated with reported cases | If the outbreak strain had WT virulence, then ∼1000 infections per case (though the clustering of cases suggests some predisposing factor) | 2 cases associated with a minimum of 400 infections (if outbreak strain had fully regained WT virulence) | Likely to be 1,000–5,000 infections/case. Full case ascertainment would suggest a max of 15,000 infections during outbreak period alone. | If the outbreak strain had WT virulence, would imply a min of 3×200 infections during the outbreak period. |
|
|
|
|
|
|
|